Imatinib is a small molecule kinase inhibitor. The BCR-ABL kinase can phosphorylate a series of downstream substrates, leading to proliferation of mature granulocytes. Bcr-Abl kinase substrate is the tyrosine. The Protein Tyrosine Kinase activity is an important requirement for malignant transformation, and that it cannot be complemented by any downstream effector, though not all interactions of BCR-ABL with other proteins are phosphotyrosine dependent.